First-Line Durvalumab plus Tremelimumab vs Platinum-Based Chemotherapy for Advanced/Metastatic NSCLC: Phase 3 NEPTUNE Study

被引：3

作者：

Mok, Tony ^{[1
]}

Schmid, Peter ^{[2
]}

De Castro, Gilberto, Jr. ^{[3
]}

Syrigos, Kostas ^{[4
]}

Martin, Claudio ^{[5
]}

Yamamoto, Nobuyuki ^{[6
]}

Aren, Osvaldo ^{[7
]}

Arrieta, Oscar ^{[8
]}

Gottfried, Maya ^{[9
]}

Jazieh, Abdul Rahman ^{[10
]}

Ramlau, Rodryg ^{[11
]}

Timcheva, Constanta ^{[12
]}

Trani, Leonardo ^{[13
]}

机构：

[1] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, Dept Clin Oncol, Shatin, Hong Kong, Peoples R China

[2] Queen Mary Univ London, Barts Canc Inst, Ctr Expt Canc Med, London, England

[3] Fac Med Usp, Inst Canc Estado Sao Paulo, Sao Paulo, Brazil

[4] Univ Athens, Athens, Greece

[5] Inst Alexander Fleming, Dept Clin Oncol, Buenos Aires, DF, Argentina

[6] Wakayama Med Univ, Dept Expt Therapeut Internal Med Resp Med & Med O, Wakayama, Japan

[7] Ciec Ctr Int Estudios Clin, Dept Oncol, Santiago, Chile

[8] Inst Nacl Cancerol Incan, Thorac Oncol Unit, Mexico City, DF, Mexico

[9] Meir Med Ctr, Dept Oncol, Kefar Sava, Israel

[10] King Saud Univ Hlth Sci Natl Guards Hlth Affairs, Dept Oncol, Riyadh, Saudi Arabia

[11] Poznan Univ Med Sci, Dept Oncol, Poznan, Poland

[12] Mhat Womens Hlth, Med Oncol Clin, Sofia, Bulgaria

[13] Astrazeneca, Royston, England

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期

关键词：

MEDI4736; tremelimumab; durvalumab; Checkpoint blockade;

D O I：

10.1016/j.jtho.2016.11.1515

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P2.06-022

引用

页码：S1084 / S1084

页数：1

共 50 条

[21] First Line Sintilimab plus Anlotinib vs Platinum-based Chemotherapy in Metastatic NSCLC (SUNRISE): Updated Efficacy and Safety Analysis
Chu, T.
Han, B.
Yu, Z.
Wang, J.
Zhao, Y.
Mu, X.
Yu, X.
Shi, X.
Shi, Q.
Guan, M.
Ding, C.
Geng, N.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S616 - S616
[22] A phase 3, randomized study of first-line durvalumab (D) ± tremelimumab (T) plus platinum-based chemotherapy (CT) vs CT alone in extensive disease small-cell lung cancer (ED-SCLC): Caspian
Paz-Ares, Luis G.
Jiang, Haiyi
Huang, Yifan
Dennis, Phillip A.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[23] Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma
Grande, Enrique
Bamias, Aristotelis
Galsky, Matthew D.
Kikuchi, Eiji
Davis, Ian D.
Arranz, Jose Angel
Kalebasty, Arash Rezazadeh
del Muro, Xavier Garcia
Park, Se Hoon
De Giorgi, Ugo
Alekseev, Boris
Mencinger, Marina
Izumi, Kouji
Puente, Javier
Li, Jian-Ri
Bernhard, Sandrine
Nicholas, Alan
Telliez, Julie
De Santis, Maria
EUROPEAN UROLOGY OPEN SCIENCE, 2023, 58 : 28 - 36
[24] Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs chemotherapy (CT) in Asian patients with metastatic NSCLC: Results from MYSTIC
Cho, B. C.
Lee, K. H.
Ahn, M-J.
Geater, S. Lucien
Ngoc, T. V.
Wang, C-C.
Cho, E. K.
Lee, J. S.
Sriuranpong, V.
Bui, Q.
Clarke, S.
Kuyama, S.
Nakagawa, K.
Liu, F.
Clemett, D.
Scheuring, U.
Peters, S.
Rizvi, N.
ANNALS OF ONCOLOGY, 2019, 30
[25] Durvalumab (D) plus /- tremelimumab (T) plus chemotherapy (CT) in first-line (1L) metastatic (m) NSCLC: AE management in POSEIDON.
Cho, Byoung Chul
Reinmuth, Niels
Luft, Alexander
Alatorre-Alexander, Jorge
Geater, Sarayut Lucien
Trukhin, Dmytro
Kim, Sang-We
Ursol, Grygorii
Hussein, Maen A.
Lim, Farah Louise
Yang, Cheng-Ta
Araujo, Luiz H.
Saito, Haruhiro
Marotti, Miriam
Barrett, Karen
Shi, Xiaojin
Peters, Solange
Garon, Edward B.
Mok, Tony S. K.
Johnson, Melissa Lynne
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[26] Caspian: Os Results from a Randomised Phase 3 Study of First-Line Durvalumab ± Tremelimumab plus Chemotherapy in ES-SCLC
Reinmuth, Niels
Paz-Ares, Luis
Chen, Yuanbin
Hotta, Katsuyuki
Trukhin, Dmytro
Statsenko, Galina
Hochmair, Maximilian J.
Ozguroglu, Mustafa
Li, Jun Ho
Voitko, Oleksandr
Poltoratskiy, Artem
Ponce, Santiago
Verderame, Francesco
Havel, Libor
Bondarenko, Igor
Kazarnowiczw, Andrzej
Losonczy, Gyorgy
Conev, Nicolay V.
Armstrong, Jon
Byrne, Natalie
Shire, Norah
Jiang, Haiyi
Goldman, Jonathan
Alt, Juergen
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 115 - 115
[27] NEPTUNE China cohort: First-line durvalumab plus tremelimumab in Chinese patients with metastatic non-small-cell lung cancer
Cheng, Ying
Zhou, Qing
Han, Baohui
Fan, Yun
Shan, Li
Chang, Jianhua
Sun, Si
Fang, Jian
Chen, Yuan
Sun, Jianguo
Wu, Gang
Mann, Helen
Naicker, Kirsha
Shire, Norah
Mok, Tony
de Castro Jr, Gilberto
LUNG CANCER, 2023, 178 : 87 - 95
[28] Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC
Chen, Pingyu
Wang, Xintian
Zhu, Shengwen
Li, Hongchao
Rui, Mingjun
Wang, Yingcheng
Sun, Haikui
Ma, Aixia
FRONTIERS IN PUBLIC HEALTH, 2022, 10
[29] ECHO-306/KEYNOTE-715: A phase 3 study of first-line epacadostat plus pembrolizumab with or without platinum-based chemotherapy vs pembrolizumab plus platinum-based chemotherapy plus placebo for metastatic non-small cell lung cancer (mNSCLC)
Hui, Rina
Munteanu, Mihaela
Zhao, Yufan
Luo, Yiwen
Samkari, Ayman
Garassino, Marina Chiara
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[30] Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial
Peters, Solange
Cho, Byoung Chul
V. Luft, Alexander
Alatorre-Alexander, Jorge
Geater, Sarayut Lucien
Laktionov, Konstantin
Trukhin, Dmytro
Kim, Sang-We
Ursol, Grygorii M.
Hussein, Maen
Lim, Farah Louise
Yang, Cheng-Ta
Araujo, Luiz Henrique
Saito, Haruhiro
Reinmuth, Niels
Lowery, Caitlin
Mann, Helen
Stewart, Ross
Jiang, Haiyi
Garon, Edward B.
Mok, Tony
Johnson, Melissa L.
JOURNAL OF THORACIC ONCOLOGY, 2025, 20 (01) : 76 - 93

← 1 2 3 4 5 →